Log in

OTCMKTS:EVTCYEvotec Stock Price, Forecast & News

$51.41
0.00 (0.00 %)
(As of 05/26/2020 04:00 PM ET)
Add
Compare
Today's Range
$51.41
Now: $51.41
$51.41
50-Day Range
$45.34
MA: $49.89
$51.80
52-Week Range
$40.42
Now: $51.41
$59.50
VolumeN/A
Average Volume315 shs
Market Capitalization$3.89 billion
P/E Ratio62.70
Dividend YieldN/A
Beta1.07
Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services. The EVT Innovate segment is involved in investing and developing proprietary assets, including early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. Evotec AG has a strategic drug discovery and development partnership with Celgene Corporation; strategic research alliance with Novo Nordisk A/S; collaboration with Sanofi; research collaboration with Almirall; research alliance with Ferring Pharmaceuticals; strategic collaboration with Centogene; collaboration with Immuneering; and drug discovery alliance with LEO Pharma. The company was founded in 1993 and is headquartered in Hamburg, Germany.
Read More
Evotec logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:EVTCY
CUSIPN/A
CIKN/A
Phone49-4056-0810

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$443.55 million
Cash Flow$1.83 per share
Book Value$6.73 per share

Profitability

Net Income$99.41 million

Miscellaneous

Employees2,617
Market Cap$3.89 billion
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive EVTCY News and Ratings via Email

Sign-up to receive the latest news and ratings for EVTCY and its competitors with MarketBeat's FREE daily newsletter.

Evotec (OTCMKTS:EVTCY) Frequently Asked Questions

How has Evotec's stock been impacted by COVID-19 (Coronavirus)?

Evotec's stock was trading at $49.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EVTCY stock has increased by 4.7% and is now trading at $51.41. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Evotec?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evotec in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Evotec.

When is Evotec's next earnings date?

Evotec is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Evotec.

How were Evotec's earnings last quarter?

Evotec AG (OTCMKTS:EVTCY) issued its quarterly earnings data on Thursday, May, 14th. The company reported $0.24 earnings per share (EPS) for the quarter. The business had revenue of $131.71 million for the quarter. Evotec had a net margin of 12.91% and a return on equity of 12.32%. View Evotec's earnings history.

Has Evotec been receiving favorable news coverage?

Media coverage about EVTCY stock has been trending negative on Wednesday, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Evotec earned a coverage optimism score of -2.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutEvotec.

Who are some of Evotec's key competitors?

Who are Evotec's key executives?

Evotec's management team includes the following people:
  • Dr. Werner Lanthaler, CEO & Member of Management Board (Age 51)
  • Mr. Enno Spillner, CFO & Member of Management Board (Age 49)
  • Dr. Cord Dohrmann, Chief Scientific Officer & Member of Management Board (Age 55)
  • Dr. Craig Johnstone, COO & Member of Management Board
  • Ms. Anja Bosler, Principal Accounting Officer and Sr. VP of Group Accounting

What is Evotec's stock symbol?

Evotec trades on the OTCMKTS under the ticker symbol "EVTCY."

How do I buy shares of Evotec?

Shares of EVTCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evotec's stock price today?

One share of EVTCY stock can currently be purchased for approximately $51.41.

How big of a company is Evotec?

Evotec has a market capitalization of $3.89 billion and generates $443.55 million in revenue each year. Evotec employs 2,617 workers across the globe.

What is Evotec's official website?

The official website for Evotec is www.evotec.com.

How can I contact Evotec?

Evotec's mailing address is Manfred Eigen Campus Essener Bogen 7, Hamburg 2M, 22419. The company can be reached via phone at 49-4056-0810 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.